Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Saved in:
| Title: | Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. |
|---|---|
| Authors: | Ostrowitzki S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bittner T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California., Sink KM; Genentech, Inc, South San Francisco, California., Mackey H; Genentech, Inc, South San Francisco, California., Rabe C; Genentech, Inc, South San Francisco, California., Honig LS; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York., Cassetta E; Fatebenefratelli Foundation, Associazione Fatebenefratelli Per la Ricerca Division, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy., Woodward M; Austin Health Continuing Care Clinical Service Unit, Heidelberg, Germany.; University of Melbourne, Melbourne, Victoria, Australia., Boada M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., van Dyck CH; Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, Connecticut., Grimmer T; Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany., Selkoe DJ; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Schneider A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Blondeau K; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Hu N; Genentech, Inc, South San Francisco, California., Quartino A; Genentech, Inc, South San Francisco, California.; Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden., Clayton D; Genentech, Inc, South San Francisco, California., Dolton M; Roche Products Australia Pty Ltd, Sydney, New South Wales, Australia., Dang Y; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Sanofi Genzyme, Waltham, Massachusetts., Ostaszewski B; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Sanabria-Bohórquez SM; Genentech, Inc, South San Francisco, California., Rabbia M; Genentech, Inc, South San Francisco, California., Toth B; Genentech, Inc, South San Francisco, California., Eichenlaub U; Roche Diagnostics GmbH, Penzberg, Germany., Smith J; Roche Products Ltd, Welwyn Garden City, United Kingdom., Honigberg LA; Genentech, Inc, South San Francisco, California., Doody RS; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California. |
| Source: | JAMA neurology [JAMA Neurol] 2022 Nov 01; Vol. 79 (11), pp. 1113-1121. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
